Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals' EBV (Epstein Barr Virus) Vaccine (268664).

Inclusion Criteria: * Healthy adolescent/adult subjects between and including 16 and 25 years of age at the time of screening. * Written informed consent obtained from the subject prior to enrolment. * Seronegative for EBV antibody. Exclusion Criteria: * Administration of immunoglobulin and/or any blood products within the three months (90 days) preceding the first dose of study vaccine or planned administration during the study period. * Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection. * Family history of congenital or hereditary immunodeficiency. * Major congenital defects or serious chronic illness. * History of any neurologic disorders or seizures, with the exception of a single febrile seizure during childhood. * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * History of intravenous drug abuse within the past 2 years. * Known or suspected allergy to any vaccine component.